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Abstract
Background: Neuroblastoma is a solid tumour of childhood often with an unfavourable outcome.
One common genetic feature in aggressive tumours is 1p-deletion.
The α-enolase (ENO1) gene is located in chromosome region 1p36.2, within the common region
of deletion in neuroblastoma. One alternative translated product of the ENO1 gene, known as MBP-
1, acts as a negative regulator of the c-myc oncogene, making the ENO1 gene a candidate as a
tumour suppressor gene.
Methods: Methods used in this study are transfection of cDNA-vectors and in vitro transcribed
mRNA, cell growth assay, TUNEL-assay, real-time RT-PCR (TaqMan) for expression studies,
genomic sequencing and DHPLC for mutation detection.
Results: Here we demonstrate that transfection of ENO1 cDNA into 1p-deleted neuroblastoma
cell lines causes' reduced number of viable cells over time compared to a negative control and that
it induces apoptosis. Interestingly, a similar but much stronger dose-dependent reduction of cell
growth was observed by transfection of in vitro transcribed ENO1 mRNA into neuroblastoma cells.
These effects could also be shown in non-neuroblastoma cells (293-cells), indicating ENO1 to have
general tumour suppressor activity.
Expression of ENO1  is detectable in primary neuroblastomas of all different stages and no
difference in the level of expression can be detected between 1p-deleted and 1p-intact tumour
samples. Although small numbers (11 primary neuroblastomas), there is some evidence that Stage
4 tumours has a lower level of ENO1-mRNA than Stage 2 tumours (p = 0.01). However, mutation
screening of 44 primary neuroblastomas of all different stages, failed to detect any mutations.
Conclusion: Our studies indicate that ENO1 has tumour suppressor activity and that high level of
ENO1 expression has growth inhibitory effects.
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Background
Neuroblastoma is the most common solid tumour of
childhood. It is a tumour of the postganglionic sympa-
thetic nervous system. The most common genetic features
of this tumour are amplification of the oncogene MYCN,
deletions of part of chromosome arm 1p, gain of parts of
17q and triploidy. MYCN amplification, 1p-loss and 17q
gain are strongly associated with aggressive tumour and
unfavourable outcome for the patient, whereas triploidy
is associated with low stage neuroblastomas and a favour-
able outcome. For review see [1].
A smallest region of overlap of deletion has earlier been
determined in primary neuroblastomas by our group to
an approximately 2 Mbp region between polymorphic
markers D1S214 and D1S244 [2,3]. Although other
research groups have defined regions telomeric to marker
D1S214 [4], still the major part of all 1p-deleted neurob-
lastoma tumours does include this region. We hypothe-
sise that this region harbours one or more tumour
suppressor genes, which plays an important role in neu-
roblastoma tumourigenesis. In previous studies a number
of different candidate genes from the critical region have
been screened for mutations and expression differences.
Some examples are TP73[5,6],  CORT  [7],  DFFA  [8,9],
UBE4B [10], APITD1 [11], KIF1B-beta [12], KIF1B-alpha
[13], SDHB [14], CDC2L1 [15,16], HKR3 [17], DAN [18],
ID3 [19], TNFR2 [20]. However, there is still no conclu-
sive evidence that anyone of these candidate genes could
function as a neuroblastoma tumour suppressor gene.
Functional evidence for a neuroblastoma tumour sup-
pressor gene on chromosome 1 was obtained in cell-
hybrid studies [21]. The addition of an entire chromo-
some 1 to a 1p-deleted cell line was shown to induce cell
death and/or differentiation indicating that it should be
possible to functionally identify the neuroblastoma
tumour suppressor gene by introducing candidate genes
into 1p-deleted neuroblastoma cells, and then monitor-
ing the cells for reduced cell growth, apoptosis and differ-
entiation.
Non-neural enolase or α-enolase (ENO1) is an enzyme in
the glycolytic pathway catalysing the formation of phos-
phoenolpyruvate from 2-phosphoglycerate. This gene
also encodes an alternatively translated product, by initi-
ating the translation at the Met-97 residue in exon 5 [22].
This product was earlier known as the Myc-binding pro-
tein-1 (MBP-1) [23]. The long 48 kDa form of α-enolase
has enzymatic activity and, depending on cell type, a cyto-
plasmic and/or nuclear localization [24], whereas the
shorter 37 kDa form (MBP-1) is preferentially localized in
the cell nuclei [25]. MBP-1 appears to function as a nega-
tive regulator of c-myc expression [26]. The c-myc pro-
tooncogene is a DNA-binding phosphoprotein that plays
an important role in cell growth regulation and differenti-
ation [27]. A major genetic feature of aggressive neurob-
lastoma tumours is amplification of the oncogene MYCN,
and this is often associated with loss of chromosome
region 1p. Even though there are similarities between the
c-myc and MYCN oncogenes, there is no evidence that
MBP-1 is able to interact with MYCN. Still it would be of
interest to investigate this further by comparing the
actions of ENO1/MBP-1 in MYCN-amplified cells relative
to cells with no MYCN-amplification.
Enforced overexpression of MBP-1  by transfection of
MBP-1  cDNA into human breast carcinoma cells was
shown to inhibit tumour formation in nude mice [28],
and the carboxyl-terminal repressor domain of MBP-1 has
been shown to regress prostate tumour growth in nude
mice [29]. Another study has shown that α-enolase is fre-
quently down-regulated in non-small cell lung cancer and
that low levels of α-enolase predicts aggressive biological
behaviour [30]. Our first hypothesis in designing this
study was that the shorter form (MBP-1) would play an
important role in cell growth regulation in neuroblast-
oma, considering its localization to the nucleus and its
known function as a negative regulator of c-myc expres-
sion, and that the longer form (ENO1) would not be
directly involved in altered cell growth. This hypothesis
was proven to be false, since we in this study could show
that the longer form (ENO1) alone has equal or stronger
effect on the cell viability and apoptosis, as do MBP-1.
In this paper we have functionally screened six candidate
genes from the 1p36.2 region (CORT, DFFA, ENO1, ICAT,
PEX14 and PGD) in neuroblastoma cells. We have further-
more performed a more detailed study of ENO1, includ-
ing its shorter translation form MBP-1, and a mutated
form of ENO1 that eliminates the possibility of produc-
tion of MBP-1, by using in vitro transcribed mRNA. Our
studies demonstrate that ENO1 overexpression in both
neuroblastoma and 293 cells significantly reduces cell
growth and induces apoptosis, implicating ENO1  in
tumourigenesis. Similar effects could be seen for both
ENO1 and MBP-1 in both MYCN-amplified cells (IMR32)
and cells with no MYCN-amplification (SK-N-AS).
Methods
cDNA-constructs
Full length IMAGE cDNA clones of the genes DFFA [Gen-
Bank:BC000037],  ENO1  [GenBank:BC009912],  ICAT
[GenBank:BC014300],  PEX14  [GenBank:BC006327],
PGD [GenBank:BC000368] (HGMP Resource Centre, UK)
and a clone for CORT  [Genbank:AF013252] (Incyte
Genomics, Palo Alto, CA) were used as templates to make
a full length PCR product not including the polyA signal
and introducing cloning sites in the ends (primer
sequences available upon request). For DFFA,  ENO1,BMC Cancer 2005, 5:161 http://www.biomedcentral.com/1471-2407/5/161
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ICAT and CORT a NotI site was introduced at the 3' end
and an EcoRI site at the 5' end. For clones PGD and PEX14
NotI  was used at both ends. The PCR products were
digested and ligated into the vector pIRES-EGFP (Clon-
tech, Palo Alto, CA), which includes the CMV promoter
for eukaryotic expression and the EGFP gene for fluores-
cence detection, using standard procedures. The resulting
clones of DFFA, PEX14 and PGD were also confirmed by
restriction digestion (data not shown). Large-scale plas-
mid DNA preparations were performed using the Qiagen
Plasmid Maxi protocol (Qiagen, Hilden, Germany). All
constructs were finally sequence confirmed by BigDyeTer-
minator sequencing, performed on ABI 3700 (Applied
Biosystems).
A mutated variant of the ENO1 cDNA was constructed by
introducing two mutations in the ENO1 sequence, elimi-
nating the alternative translation start codons of MBP-1
(Fig. 1A). The mutations were introduced into the ENO1
sequence by PCR using the double-mutated forward
primer fp1: 5'-CTGATCATCGAGATCGA TGGAAC-3', in
combination with the reverse primer rp2: 5'-ACAAA-
GAATTCCGG GGATCTAGCCT GTGG-3' for 30 cycles,
using the ENO1-pIRES-EGFP construct as a template. 0.1
µl of the PCR-product was then used as template in an
additional PCR reaction using the primers fp3: 5'-CAG-
CAGCGGCCGCTTCCTCTC CTAGGCG-3' and rp2: 5'-
ACAAAGAATTCCGGGGATCTAGCCTGTGG-3' for 30
cycles of PCR, to incorporate the mutations in the full-
length gene product. The ENO1  mutant fragment was
cloned into the pIRES-EGFP vector by EcoRI/NotI diges-
tion and religation (Fig. 1B). The mutations were also
confirmed by digestion of the PCR product with BclI and
ClaI that only digest the mutated sequence (Fig. 1C).
A. ENO1, ENO1-mut and MBP-1-constructs with translation starts (ATG) and mutated (ATG→ATC) sites in ENO1-mut at  positions 374 and 383 indicated Figure 1
A. ENO1, ENO1-mut and MBP-1-constructs with translation starts (ATG) and mutated (ATG→ATC) sites in ENO1-mut at 
positions 374 and 383 indicated. The mutations introduce Bcl I and Cla I restriction enzyme sites respectively. B. Size determi-
nation of cDNA-constructs in pIRES-EGFP-vector by NotI/EcoRI-digest. C. Confirmation of mutations in ENO1-mut DNA by 
ClaI and BclI digests.
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Production of in vitro transcribed mRNA
A DNA fragment containing the coding region of the
ENO1 gene linked to the Sp6 promoter sequence and a
polyA tail at the end of the fragment was constructed by
PCR. The primers used for the ENO1  and  ENO1mut
mRNAs were fp: 5'-ATTTAGGTGACACTATAGAAGAGAC-
CCAGTGGCTAGAAGTTCACCATG-3' and rp: 5'-
GG(T)30CCGGGGATCTAGCCTGTGG-3'. Similarly, the
primers for MBP-1  mRNA were fp: 5'-
ATTTAGGTGACACTATAGAAGAGAACAAGAGAAGATT-
GACAAACTGATG-3' and rp: 5'-
GG(T)30CCGGGGATCTAGCCTGTGG-3' using ENO1-
mut-pIRES-EGFP-vector as a template. The PCR was per-
formed using High Fidelity Taq Polymerase (Roche, Man-
nheim, Germany) according to supplier's protocol with
an annealing temperature of 58°C and 25 cycles of PCR.
500 ng of the PCR-product (663 bp) was used as a tem-
plate for in vitro mRNA using mMESSAGE mMachine
(Ambion, Austin, TX). The procedure was according to
supplier's protocol using 4 hours incubation at 37°C. The
mRNA was DNaseI treated for 15 min at 37°C and LiCl-
precipitated before size and concentration evaluation by
agarose gel electrophoresis. The control EGFP mRNA was
produced using an EcoRI-digested Sp6-EGFP vector as
template in the in vitro mRNA reaction.
The concentrations of EGFP and ENO1 mRNA prepara-
tions were evaluated on agarose and adjusted to be equal
for transfection studies.
Tissue culture
The 1p-deleted neuroblastoma cell lines SK-N-AS and
IMR32 (MYCN-amplified) (ATCC, Manassas, VA), the
human kidney derived cell line 293 and the human eryth-
roleukaemic cell line K562 were cultured in Dulbecco's
Modified Eagle Medium (DMEM) with 10% Fetal Calf
Serum (FCS) at 37°C using standard procedures. On the
day before transfection the cell lines were split into new
culture flasks and their viability tested by Trypan Blue
staining. Flasks with 60–80% cell confluence were used in
transfection experiments. Immediately before the trans-
fection procedure the SK-N-AS cells, the IMR32 cells and
the 293 cells were trypsinized and washed twice with PBS
and the cell numbers were calculated using Trypan Blue
staining. The suspension cells K562 were used only if the
viability was 90% or more on the day of transfection.
Transfection of cDNA vectors
Transfection of the cell lines SK-N-AS and 293 with the
cDNA constructs was performed by electroporation using
10 µg of DNA in 4 × 106 cells in a 0.4 cm cuvette in 500 µl
Opti-MEM I (Invitrogen, Carlsbad, CA) at 300 V, 950 µF,
∞ Ω, using a Bio-Rad Gene Pulser II (Bio-Rad, Hercules,
CA). The transfection efficiency of SK-N-AS and 293 was
tested by transfection of the plasmid pEGFP-N22, fol-
lowed by estimation of the number of green cells detected
by FACS analysis after two days of growth in DMEM 10 %
FCS. The transfection efficiency for the SK-N-AS and 293
cells was approximately 90% under these conditions.
For IMR32 cells, transfections were performed using Lipo-
fectamine™ 2000 (Invitrogen). 12 µg of DNA and 25 µl of
Lipofectamine™ 2000 in 1200 µl Opti-MEM I were used
for transfecting 106 cells in 5 ml of DMEM, 10% FCS.
Transfection efficiency was estimated to be 60 % by fluo-
rescence microscopy of pEGFP-N22 transfected cells, two
days after transfection.
Transfection with all plasmid constructs was performed
twice using SK-N-AS cells. The ENO1 construct and empty
vector control were also transfected in four different
experiments into SK-N-AS cells and twice into IMR32 and
293 cells.
Transfection of mRNA
The transfections were performed in a 12-well plate using
4 × 105cells/well for SK-N-AS and K562 cells and 7 × 105
cells/well for 293 cells, all in 2 ml DMEM with 10% FCS
per well. For each transfection a total of 1.5 µg of mRNA
(A: 1.5 µg EGFP mRNA; B: 0.3 µg ENO1 mRNA + 1.2 µg
EGFP  mRNA; C: 1.5 µg ENO1  mRNA) and 5 µl Lipo-
fectamine™ 2000 were used. The mRNA and the Lipo-
fectamine™ 2000 were incubated together for 30 min in
200 µl Opti-MEM I and then added to the cell suspen-
sions. The cells were immediately divided into 96-well
plates at 104 cells/well (SK-N-AS, K562) or 1.7 × 104 cells/
well (293) (50 µl/well), and incubated at 37°C for 5
hours before an extra 50 µl DMEM with 10% FCS was
added. The cells were incubated for 1–4 days in 37°C for
cell growth studies.
Apoptosis assay
After transfection, the cells were allowed to attach for two
hours in a tissue culture plate (6 well) before the medium
was replaced by fresh DMEM 10% FCS. Then the cells
were grown for two days before all cells, both in medium
and attached cells (trypsinized) were washed with PBS
and fixed in a final concentration of 2% paraformalde-
hyde.
The fixed cells were TUNEL stained using the In Situ Cell
Death Detection Kit TMR-red kit (Roche, Mannheim, Ger-
many) according to supplier's protocol. This stains all
apoptotic cells red. The cells were then analysed by FACS
analysis.
Cell growth assay
After transfection, the cells were divided into 96-well
plates. Cells with each different construct were dividedBMC Cancer 2005, 5:161 http://www.biomedcentral.com/1471-2407/5/161
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into 8 wells/plate, in four different plates with 104 cells in
100 µl DMEM 10 % FCS per well. One plate was used
every day for four days after transfection to monitor cell
growth. 20 µl of CellTiter96 Aqueous One Solution (Cell
Proliferation Assay, Promega, Madison, WI) was added to
each well and incubated in a humid dark chamber at
37°C for four hours. The absorbance was detected at 490
nm by an ELISA-reader (Labsystems Multiscan RC, Hel-
sinki, Finland). The results were compared to a standard
curve to calculate the number of viable cells per well each
day. The mean number of cells in the 8 wells evaluated per
day per construct was used in evaluating the results.
The transfection efficiency was evaluated one day after
transfection using fluorescence microscopy, by counting
the number of green cells in the pEGFP-N22 or EGFP
mRNA experiments.
Patient material
Frozen (-70°C) tumour samples from 44 neuroblastoma
patients; 4 Stage 1 (1 1p-deleted), 4 Stage 2, 14 Stage 3 (7
1p-deleted), 20 Stage 4 (14 1p-deleted), 2 Stage 4S; 2 gan-
glioneuromas and 2 teratomas (1 1p-deleted) were used
in the study.
The tumours were staged according to the International
Neuroblastoma Staging System criteria [31,32]. The 1p-
deletion status has been previously evaluated [2,16]. DNA
was extracted from patient samples using standard proce-
dures.
Expression studies of ENO1
cDNA preparation
Total RNA was extracted from frozen neuroblastoma
tumour tissue from 11 primary neuroblastomas; 4 Stage 2
tumours from patients with no evidence of disease after
treatment; 7 Stage 4 tumours (4 1p-deleted), all from
patients dead of disease and 7 neuroblastoma cell lines (4
1p-deleted) using RNeasy RNA extraction kit (Qiagen).
2.4 µg total-RNA of each sample was reversed transcribed
to cDNA using Superscript II (Amersham, Buckingham-
shire, UK) and random hexamer primers, all according to
supplier's protocol.
Real time RT-PCR
TaqMan primers and probes were derived from the com-
mercially available TaqMan®  Assays-on-Demand Gene
Expression Products. To select the most appropriate
endogenous control for the real-time RT-PCR quantifica-
tion analysis of neuroblastoma primary tumours, we used
TaqMan Human Endogenous Control Plate (catalog
number: 4309921, Applied Biosystems, Foster City, CA).
Analysis was performed according to supplier's protocol.
To select the most appropriate endogenous control for the
real-time PCR quantification analysis, we tested eight dif-
ferent primary NB samples of different stages for their
expression levels of ten commonly used housekeeping
genes. GUSB (β-glucuronidase) and B2M (β2-microglobu-
lin) showed least variations in ∆CT  levels, and were
expressed at constant levels in all samples regardless of
NB-stage. GUSB was selected, and further used as an inter-
nal reference for normalization in the real-time PCR
quantification analysis [9].
Real-time RT-PCR was performed in 384-well plates using
ABI PRISM® 7900HT Sequence Detection System (Applied
Biosystems). Amplification reactions (10 µl) were carried
out in duplicate with 1 µl of 1:10 diluted template cDNA
according to manufacturer's protocol (Applied Biosys-
tems). In each assay, a standard curve with six cDNA dilu-
tions was recorded and two non-template controls were
included.
Quantification was performed by the standard-curve
method. The mean CT-value for duplicates was calculated,
and the gene concentration (or gene copy number) of test
samples was interpolated based on standard curves. All
samples were normalized by dividing the concentration of
the test gene with the concentration of the housekeeping
gene β-glucuronidase (GUSB) in the same cDNA sample.
Statistical analysis
Statistical analysis was done with Student's two-sided t-
test on each group of tumors; low-stage and high stage
tumors; and for 1p-deleted and not 1p-deleted tumors for
the expression study.
In the transfection study, Student's two-sided t-test was
used to compare cell numbers in each experiment at 1, 2,
3 and 4 days after transfection.
Mutation screening
Mutation screening of all exonic sequences, selected
intronic sequences and the promoter region of ENO1 was
performed on genomic DNA from 48 primary neuroblas-
toma tumours of all different stages. The different regions
were amplified by PCR and the PCR products were
screened for mutations using either BigDyeTerminator
sequencing, performed on ABI 3700 (Applied Biosys-
tems) and/or DHPLC (WAVE) (Becton, Dickinson and
Company) all according to general protocols of the sup-
pliers. PCR-primers were designed to include the entire
exon plus exon-intron boundaries. PCR primers and
amplification data are available on request.BMC Cancer 2005, 5:161 http://www.biomedcentral.com/1471-2407/5/161
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Results
Functional studies
TUNEL staining, followed by FACS-analysis, of ENO1-
transfected SK-N-AS neuroblastoma cells two days after
transfection showed a higher degree of apoptotic cells
(59%) than with the empty vector control (9%) or any of
the other constructs tested (8–26% apoptotic cells),
(Table 1, Fig. 2).
The DNA transfection studies also showed that the ENO1
gene did have the strongest and most consistent effect
(approximately 20% reduction) on the growth rate of 1p-
deleted neuroblastoma cells (SK-N-AS and IMR32) com-
pared to an empty vector control (Table 2, Fig. 3). In the
same assay, DFFA, PGD and PEX14 showed an approxi-
mately 10% reduction in cell growth (SK-N-AS), ICAT did
not show any reduction and CORT showed very variable
effects (from -10% to 18% reduction) (Table 2, Fig. 3).
Transfection experiments using the ENO1-gene compared
to empty vector control were also performed in the 1p-
deleted and MYCN-amplified neuroblastoma cell line
IMR32 and the non-neuroblastoma cell line 293. These
experiments showed that ENO1 reduced cell growth by
20–30 % in all three cell lines (Table 2).
Interpretation of cell growth studies after transfection of
plasmids carrying various genes may be complicated by
the fact that only a fraction of cells express the relevant
gene, whereas the growth of the remaining cells may con-
tinue unaffected. In an effort to ensure that most cells
express the relevant gene after transfection, we have also
investigated transfection of each one of the genes as in
vitro transcribed mRNA. Preliminary studies with EGFP-
mRNA showed that the transfection efficiency, as deter-
mined by fluorescence microscopy 24 hours after transfec-
tion, was 90% for SK-N-AS cells, 60% for K562 cells and
90% for 293 cells.
Our mRNA-transfection experiments showed that by add-
ing 1.5 µg of ENO1- or ENO1-mut-mRNA to the neurob-
lastoma cell line SK-N-AS, the cell numbers were reduced
by 60% after 24 hours, and by 80% after 2–4 days of incu-
bation, compared to EGFP-mRNA transfected cells (Table
3, Fig. 4A &4B). On the other hand, 1.5 µg MBP-1-mRNA
reduced the cell growth rate by 50% after 24 hours and
70% 2–4 days after transfection (Table 3, Fig. 4B), indicat-
ing that MBP-1-mRNA is less effective than the full length
transcripts.
When 0.3 µg ENO1-mRNA or ENO1-mut-mRNA mixed
with 1.2 µg of EGFP-mRNA were used, the reduction in
cell numbers after 24 hours was 40%, and 60% respec-
tively after 2–4 days. As with the 1.5 µg experiment, 0.3 µg
MBP-1-mRNA mixed with 1.2 µg of EGFP-mRNA gave a
lower reduction of 30% after 24 hours, and 40% 2–4 days
after transfection (Table 3, Fig. 4C).
In 293 cells a large reduction in cell numbers in the 1.5 µg
ENO1-mRNA experiments could be seen after 24 hours
(50%), and after 2–4 days (90%) compared to EGFP
transfected control cells (Table 3, Fig. 4A). For 1.5 µg
MBP1- or ENO1-mut-mRNA the reduction in 293 cells
was 40% after 24 hours, and 70–80% 2–4 days after trans-
fection. A parallel experiment with 0.3 µg ENO1-mRNA
showed about 60% reduction 2–4 days after transfection
compared to control cells, while in the same experiment
ENO1-mut and MBP-1 mRNAs showed a 30% and a 50%
reduction respectively (Table 3).
In K562 cells, the cell numbers 24 hours after transfection
were not significantly different between experiments
(Table 3).
FACS results of SK-N-AS cells two days after transfection of  empty pIRES-EGFP-vector (black line) and ENO1-pIRES-EGFP  (grey line) Figure 2
FACS results of SK-N-AS cells two days after transfection of 
empty pIRES-EGFP-vector (black line) and ENO1-pIRES-EGFP 
(grey line). The cells were TUNEL stained using TMR-red 
labelled nucleotides to label all apoptotic cells red. There is a 
clear increase of the number of red cells (FL2) in ENO1 
transfected cells compared to empty vector control.
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Table 1: Induction of apoptosis two days after transfection of 
cDNA constructs in SK-N-AS neuroblastoma cells.
Gene % Apoptotic cells
Empty vector 9 %
ENO1 59 %
CORT 19 %
DFFA 21 %
ICAT 26 %
PEX14 8 %
PGD 9 %BMC Cancer 2005, 5:161 http://www.biomedcentral.com/1471-2407/5/161
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Expression studies
No difference in expression levels could be detected
between 1p-deleted cell lines (average relative concentra-
tion of 1.07) and 1p-intact cell lines (average relative con-
centration of 1.08). Also in Stage 4 neuroblastoma
primary tumours, no difference in ENO1-expression
could be detected between 1p-deleted (average relative
concentration 0.25) and 1p-intact samples (average rela-
tive concentration of 0.19) (Fig. 5).
Real time-PCR studies of the ENO1 gene on cDNA-sam-
ples showed a 55% reduction (p = 0.01) of ENO1-mRNA
levels in stage 4 neuroblastoma tumours compared to
stage 2 tumour levels (average relative concentration of
0.5 in stage 2 tumours compared to 0.23 in stage 4
tumours). This reduction was independent on the 1p-
deletion status of the tumour sample (Fig. 5).
Mutation screening
The mutation screening of the promoter region and of all
exonic sequences of ENO1, including exon/intron bound-
aries, and of introns 5–7 in 48 primary neuroblastoma
samples of different stages did not reveal any mutations
(data not shown).
Discussion
The aim of this study was to functionally identify a
tumour suppressor gene in the commonly deleted region
1p36 in advanced stage neuroblastoma tumours. We were
in fact able to identify one gene, ENO1, located in the
smallest region of overlap of deletion in neuroblastoma,
which did seem to have tumour suppressor activity. That
is, by introducing this gene as a cDNA construct into neu-
roblastoma cells, the number of viable cells over time was
reduced, and the number of apoptotic cells was increased.
These two results are probably just two ways of monitor-
ing the same thing. A higher degree of cell death will obvi-
ously slow down number of viable cells over time. We
also tested the ability of ENO1 cDNA to slow down cell
growth in other cell types that did not have a deletion of
1p. Here we choose the 293 cell line (human transformed
kidney cells). Other cells that could add valuable informa-
Table 2: Effects of various cDNA constructs on cell growth after transfection into neuroblastoma and other tumour cell lines.
Cell Line Gene day % decrease in number of cells +/-SD number of experiments p-value: test
SK-N-AS Empty vector (control) - 3 × 8
ENO1 1 22 +/- 8 3 × 8 < 0.001
2 21 +/- 4 3 × 8 0.004
3 13 +/- 3 3 × 8 0.04
4 27 +/- 12 3 × 8 < 10-5
CORT 1 3 +/- 7 1 × 8 > 0.05
2 -10 +/- 14 1 × 8 > 0.05
3 18 +/- 14 1 × 8 0.004
4 4 +/- 8 1 × 8 > 0.05
DFFA 1 2 +/- 8 1 × 8 > 0.05
2 6 +/- 11 1 × 8 > 0.05
3 19 +/- 12 1 × 8 0.002
4 14 +/- 6 1 × 8 < 10-6
ICAT 1 -6 +/- 10 1 × 8 0.04
2 -3 +/- 9 1 × 8 > 0.05
3 0 +/- 23 1 × 8 > 0.05
4 -2 +/- 6 1 × 8 > 0.05
PEX14 1 1 +/- 10 1 × 8 > 0.05
2 -9 +/- 18 1 × 8 > 0.05
3 15 +/- 18 1 × 8 0.02
4 9 +/- 7 1 × 8 0.001
PGD 1 12 +/- 8 1 × 8 < 0.001
2 -1 +/- 16 1 × 8 > 0.05
3 24 +/- 15 1 × 8 < 0.001
4 11 +/- 7 1 × 8 < 10-4
IMR32 ENO1 1 12 +/- 16 1 × 8 0.02
2 23 +/- 14 1 × 8 0.01
3 14 +/- 14 1 × 8 < 0.001
4 18 +/- 8 1 × 8 < 10-5
293 ENO1 1 15 +/- 20 1 × 8 0.03
2 49 +/- 29 1 × 8 0.006
3 19 +/- 10 1 × 8 < 0.001
4 46 +/- 9 1 × 8 < 10-7BMC Cancer 2005, 5:161 http://www.biomedcentral.com/1471-2407/5/161
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tion would be a neuroblastoma cell line with intact 1p
(such as SK-N-SH or SK-N-F1), we were though unable to
get a satisfactory transfection efficiency in these cell lines
for this study, and thus choose to use the 293 cells that
worked very well, that also adds valuable information
about the general effect of ENO1 on cells with intact 1p.
In this study we monitor viable cells over time after trans-
fection, thus it is crucial to have high percentage of trans-
fected cells otherwise your experiment would easily be
overgrown by the untransfected cell population. After
transfection of ENO1 into the 293 cells the same results
were obtained as with the neuroblastoma cell lines, that
is, the number of viable cells over time was reduced by
20–40 %. These results are concordant with the results of
Ray and co-workers that transfection of MBP-1  into
human breast carcinoma cells showed reduction of cell
growth and inhibition of tumour formation in nude mice
[28]. MBP-1 was later demonstrated to be a shorter trans-
lational variant of the ENO1 gene [22,25]. The localiza-
tion of the gene in the 1p36.2 chromosomal region makes
it a very interesting gene for neuroblastoma tumourigene-
sis and one hypothesis is that one deleted copy of ENO1
in the neuroblastoma cells would result in lower levels of
α-enolase, and thus these cells would have a stronger
response when more ENO1-mRNA is added. However, in
this study we did see an equally strong effect in the chro-
mosome 1 intact cells 293. Maybe the level of ENO1 is
crucial in the cells, and by adding too much of this gene
product shifts the balance easily and makes the cell go
into apoptosis. Also we could see in the ENO1-expession
study that the 1p-deleted cell lines did not have lower lev-
els of ENO1-mRNA compared to the 1p-intact cell lines.
This adds to the hypothesis that the level of ENO1 expres-
sion might be crucial. One hypothesis was that it might be
a difference in the response to added ENO1 in MYCN-
amplified cells (IMR32) and cells with normal MYCN
(SK-N-AS), since the shorter form of ENO1  (MBP-1)
appears to function as a negative regulator of c-myc
Cell growth curves of cDNA-transfected cells monitored for 3 days after transfection Figure 3
Cell growth curves of cDNA-transfected cells monitored for 3 days after transfection. The average number of cells in 8 sepa-
rate experiments is shown at each time point for each construct. Standard deviation is indicated with a bar. A: Cell growth 
after transfection of five different constructs compared to empty vector (pIRES-EGFP) control in SK-N-AS cells. Using Stu-
dents T-test, no significant differences in cell number compared to control cells could be detected for the first two days after 
transfection for any of the constructs, three days after transfection DFFA (p = 0.002), CORT (p = 0.004) and PGD (p < 0.001) 
showed significant difference. B: Cell growth after transfection of ENO1 compared to empty vector control. Significant differ-
ences in cell number was detected day 1 (p < 10-8) and day 2 (p < 10-4), the difference was not significant day 3 after transfec-
tion.
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Table 3: Effects of in vitro transcribed ENO1 mRNA constructs on cell growth after transfection into neuroblastoma (SK-N-AS), 293 and K562 cell lines.
cell line SK-N-AS 293 K562
mRNA day % decrease in 
number of
cells +/-SD
no of exp p-value test % decrease in
number of
cells +/-SD
no of exp p-value test % decrease in 
number of
cells +/-SD
no of exp p-value test
1.5 µg EGFP - 4 × 8 - 3 × 8 - 2 × 4
1.5 µg ENO1 1 58 +/- 12 4 × 8 < 10-5 52 +/- 11 3 × 8 < 10-3 -11 +/- 19 2 × 4 > 0.05
2 81 +/- 11 < 10-9 85 +/- 8 < 10-5 13 +/- 34 > 0.05
3 79 +/- 12 < 10-9 89 +/- 16 < 10-5 9 +/- 11 > 0.05
4 76 +/- 17 < 10-9 87 +/- 20 < 10-5 10 +/- 9 0.03
0.3 µg ENO1 1 39 +/- 25 3 × 8 0.02 38 +/- 27 2 × 8 < 10-4 -14 +/- 14 1 × 4 0.04
2 63 +/- 15 < 10-5 64 +/- 36 < 10-4 6 +/- 11 > 0.05
3 60 +/- 11 < 10-5 60 +/- 54 < 10-4 4 +/- 10 > 0.05
4 64 +/- 13 < 10-3 59 +/- 52 < 10-5 -3 +/- 9 > 0.05
1.5 µg ENO1-mut 1 65 +/- 26 2 × 8 0.007 44 +/- 9 1 × 8 < 10-3 -6 +/- 14 2 × 4 > 0.05
28 4  + / -  8 < 10-3 77 +/- 4 < 10-6 20 +/- 8 0.004
38 4  + / -  8 < 10-4 73 +/- 6 < 10-4 16 +/- 13 0.03
48 4  + / -  7 < 10-3 63 +/- 6 < 10-6 5 +/- 11 > 0.05
0.3 µg ENO1-mut 1 66 +/- 8 1 × 8 < 10-3 20 +/- 13 1 × 8 0.02 -18 +/- 13 1 × 4 0.01
28 2  + / -  4 < 10-6 50 +/- 7 < 10-4 8 +/- 12 > 0.05
37 0  + / -  7 < 10-4 28 +/- 15 0.007 9 +/- 13 > 0.05
47 2  + / -  6 < 10-4 29 +/- 6 < 10-4 -1 +/- 11 > 0.05
1.5 µg MBP-1 1 45 +/- 21 4 × 8 < 10-3 41 +/- 8 3 × 8 0.005 -9 +/- 16 2 × 4 > 0.05
2 67 +/- 13 < 10-7 75 +/- 10 < 10-4 10 +/- 12 > 0.05
3 68 +/- 15 < 10-6 82 +/- 25 < 10-4 1 +/- 8 > 0.05
4 64 +/- 20 < 10-7 76 +/- 31 < 10-4 5 +/- 9 > 0.05
0.3 µg MBP-1 1 25 +/- 18 3 × 8 > 0.05 50 +/- 38 2 × 8 0.02 -14 +/- 14 1 × 4 0.04
2 47 +/- 18 0.001 56 +/- 18 < 10-5 4 +/- 18 > 0.05
33 8  + / -  7 0.001 44 +/- 46 < 10-3 -11 +/- 17 > 0.05
4 37 +/- 19 0.006 42 +/- 34 < 10-4 -2 +/- 8 > 0.05BMC Cancer 2005, 5:161 http://www.biomedcentral.com/1471-2407/5/161
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Cell growth curves of cell lines SK-N-AS, 293 and K562 after transfection of in vitro transcribed mRNA and monitoring for 4  days after transfection Figure 4
Cell growth curves of cell lines SK-N-AS, 293 and K562 after transfection of in vitro transcribed mRNA and monitoring for 4 
days after transfection. The average number of cells in 8 separate experiments is shown at each time point for each construct. 
Standard deviation is indicated with a bar. A: Two different amounts of mRNA have been used for ENO1-mRNA: 1.5 (1.5 µg 
ENO1-mRNA) or 0.3 (0.3 µg ENO1-mRNA + 1.2 µg EGFP-mRNA), compared to 1.5 µg EGFP-mRNA and lipofectamine only. 
There is strong statistical significance (p << 0.001) for difference in cell numbers between the ENO1-mRNA-experiments and 
the EGFP-mRNA experiments in SK-N-AS and 293-cells (exact p-values for each day are listed in Table 3), in K562 cells the dif-
ference was not significant. B: Cell growth curves of SK-N-AS cells after transfection of 1.5 µg of ENO1, ENO1-mut and MBP-1 
mRNAs and monitoring for 4 days. The difference in cell numbers between ENO1 and MBP-1 was significant for day 2–4 (p = 
0.02), ENO1 and ENO1-mut did not significantly differ. C: Cell growth curves of SK-N-AS cells after transfection of 0.3 µg 
ENO1, ENO1-mut and MBP-1 mRNAs and monitoring for 4 days. The difference in cell numbers between ENO1 and MBP-1 was 
significant for day 2 (p = 0.006), 3 (p = 0.001) and 4 (p = 0.02). ENO1 and ENO1-mut did not significantly differ.
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expression [26]. No difference could however be seen in
the response in these two cell lines, indicating that ENO1
has growth inhibitory properties independent of effects
on MYCN regulation.
We could not detect a consistent reduction in cell growth
with the other gene constructs tested. Also we could not
detect any clear increase in apoptotic cell numbers (Table
1), and no obvious signs of differentiation, although our
data do not fully exclude a role for one or more of these
genes in the development of neuroblastoma. Noteworthy
is also another gene, APITD1, recently localised to this
region of interest. APITD1 could be shown to slow down
cell growth and induce apoptosis in neuroblastoma cells
[11]. We can hypothesise that if a number of genes in this
specific region have tumour suppressor activity, a small
reduction in expression of all these genes can give a sub-
stantial effect on cell growth. A recent study has indeed
shown that there are numerous genes from the 1p36-
region down-regulated in aggressive neuroblastoma
tumours [33].
In order to further investigate the ability of ENO1 to slow
down cell growth, and to compare the different transla-
tion products of ENO1 in a functional manner, we con-
structed one mutated form of ENO1, ENO1-mut, which
would eliminate the possibility for the alternative form
MBP-1 to be translated (Fig. 1). We used the ENO1 cDNA
vector as a template for in vitro mRNA to make ENO1
mRNA and a shorter form only including the MBP-1-part
of the gene to make MBP-1-mRNA. The ENO1-mut con-
struct was used as a template for in vitro ENO1-mut-
mRNA.
We could show that ENO1  mRNA has a strong, dose
dependent, inhibitory effect on cell growth in neuroblast-
Expression of ENO1 in neuroblastoma cell lines and primary neuroblastoma tumours using real-time-PCR Figure 5
Expression of ENO1 in neuroblastoma cell lines and primary neuroblastoma tumours using real-time-PCR. Relative concentra-
tions of ENO1-mRNA in relation to the concentration of the housekeeping gene GUSB for each sample are indicated on the y-
axis. The samples are grouped into five groups: neuroblastoma cell lines, with and without 1p-deletion; stage 2 tumours; stage 
4 tumours, with and without 1p-deletion. The 1p-deletion-status of each sample is indicated at the bottom. For each group the 
average value is indicated by a dotted line. A difference in expression could be detected between stage 2 tumours and stage 4 
tumours (p = 0.01). No difference in expression could be detected between 1p-deleted samples and not 1p-deleted samples.
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oma cells (SK-N-AS). By adding equal amounts of ENO1-
mRNA and control-mRNA (EGFP) to the cells, the
number of viable cells in the cell culture was decreased by
80% two days after transfection in the ENO1-mRNA-
experiment. If 4/5 of the ENO1-mRNA was exchanged
with control-mRNA the decrease was 60% two days after
transfection (Table 3, Fig. 4). This indicates that ENO1
acts in a dose dependent manner, suggesting that cellular
levels of ENO1 might play a crucial role in regulating
apoptosis and proliferation in neuroblastoma cells.
Surprisingly the mutated ENO1-mut-mRNA showed very
similar effects as the wild type ENO1-mRNA. This might
be explained by the fact that ENO1 in fact can bind to the
same sites as MBP-1 and act as a transcription factor, even
though not as efficiently [22]. Maybe by adding very large
amounts of mRNA, this difference is overruled. However,
an alternative explanation is that the enolase itself has
tumour suppressor activity. This is supported by the
observation that 0.3 µg ENO1 mRNA induces a stronger
inhibition in cell growth rate (60%) than the same
amount of MBP-1-mRNA (40%) in neuroblastoma cells.
A strong effect could also be seen in 293-cells by adding
ENO1-mRNA. 80–90% reduction was observed in the 1.5
µg mRNA experiment, while a lower reduction (60%) was
observed when 0.3 µg mRNA was used, as was the case
with SK-N-AS cells.
A difference between the different mRNAs could also be
seen in the 1.5 µg experiment where MBP-1 and ENO1-
mut showed a weaker effect than ENO1. Also in the
ENO1-mut and MBP-1 experiments, a smaller effect was
observed with a lower amount of mRNA (0.3 µg). We con-
clude that over-expression of ENO1 has the same effect in
both neuroblastoma cells and transformed kidney cells,
and that ENO1 can function as a general tumour suppres-
sor.
However, the transfection of ENO1-mRNA into K562
cells, a human erythroleukemia cell line, shows only
minor differences with control mRNA (Table 3, Fig. 4).
This indicates that ENO1-mRNA has no general toxicity to
cells but seems to work through one or more specific path-
ways. ENO1-mRNA does not seem to activate any cell
death or growth suppression pathway in the lymphoblast
cell line K562, as it seems to do in the neuroblastoma cell
line SK-N-AS and the transformed kidney cell line 293.
But these are indeed very different types of cells, and are
likely to be defective in different cellular pathways.
In order to see whether ENO1 was equally expressed in
both low stage and advanced neuroblastomas, and also to
compare this with the mRNA-levels in neuroblastoma cell
lines, we conducted a real-time-PCR-study using Taqman.
Surprisingly no difference in the ENO1-mRNA levels
could be detected between 1p-deleted tumours and 1p-
intact tumours, neither in the cell lines nor in primary
Stage 4 neuroblastoma tumours (Fig. 5). The loss of one
allele seems either to be compensated in these cells, or the
levels of ENO1-mRNA in the aggressive Stage 4 tumours
are suppressed by a different mechanism in the 1p-intact
Stage 4 tumours. Even though small sample number (11
primary tumours), we could detect a difference (p = 0.01)
in the levels of ENO1-mRNA in Stage 4 neuroblastomas
compared to Stage 2 neuroblastomas (Fig. 5). This still
needs further studies to be confirmed but one could spec-
ulate that the ENO1-mRNA level might be of importance
in the aggressiveness of neuroblastoma tumours, as seen
in non-small cell lung cancer [30]. The cell lines showed a
higher relative concentration of ENO1 than any of the pri-
mary tumours (Fig. 5). This might be explained by the dif-
ferent surroundings and state of cells in culture compared
to primary tumour cells (Fig. 5). The fact that by adding
extra  ENO1-mRNA to the cell lines, even though they
expressed ENO1 already, made them apoptotic, adds to
the hypothesis that the levels of this mRNA might be cru-
cial.
We also did a mutation screening of the exonic sequences
of ENO1, including exon/intron boundaries, and of the
intronic sequences between exons 4–8, in order to cover
the region around the alternative translation start of MBP-
1, in genomic DNA of 44 primary neuroblastoma
tumours of all different stages. However, no mutations
could be found in these regions, indicating that changes in
the level of ENO1 expression may result from other types
of mutations or from changes in regulatory mechanisms.
Conclusion
In conclusion, our studies demonstrate that ENO1, a gene
mapping to a region commonly deleted in advanced neu-
roblastoma tumours, can act as a strong tumour suppres-
sor by slowing down the cell growth and inducing
apoptosis. Although we could not identify any mutations
in the coding sequence and immediate promoter region
of the gene in 48 primary tumour samples, our studies
suggest that variations in the level of expression of the
gene can play a role in regulating apoptosis and cell pro-
liferation in neuroblastoma. To prove the hypothesis of
the level of ENO1 expression being crucial, future investi-
gations could involve silencing of ENO1 in neuroblast-
oma cells in vitro, by gene knock down experiments and/
or siRNA targeted to the ENO1-mRNA, to detect whether
this, opposite adding extra ENO1-mRNA, increases the
growth rate. Deletion of the 1p chromosomal region is
obviously one way to achieve a reduction in expression of
ENO1, but it is not clear whether a reduction in the
expression of the second allele is also necessary through
other mechanisms in neuroblastoma.BMC Cancer 2005, 5:161 http://www.biomedcentral.com/1471-2407/5/161
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